PharmaShots | Incisive News in 3 Shots

Subscribe Now

Dyne Therapeutics

Dyne Therapeutics’ DYNE-251 Receives the US FDA’s Fast Track Designation for the Treatment of Duchenne Muscular Dystrophy

Dyne Therapeutics’ DYNE-251 Receives the US FDA’s Fast Track Designation for the Treatment of Duchenne Muscular Dystrophy

November 1, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us